This regional assessment compiles national data from 28 Asia-Pacific countries as an early baseline after the 2024 UN General Assembly political declaration on antimicrobial resistance and ahead of its 2030 goals. Nearly all participating countries report a national action plan and reference-laboratory capacity, but structural readiness does not equal strong implementation: 15 of 27 receive less than 30% of total AMR funding from domestic sources, only 11 plans contain numerical targets, and just 16 countries report basic water, sanitation, hygiene, and waste services in more than 75% of health facilities. The results are best used as a monitoring baseline, not evidence that population-health outcomes have improved.
Key findings
- Twenty-seven countries endorsed at least one multisectoral national AMR action plan, but only 11 plans included numerical targets, revealing a gap between having policy and being able to track measurable delivery.
- Fifteen of 27 countries, or 56%, received less than 30% of total AMR funding from domestic sources. This signals financing vulnerability but does not quantify budget size or adequacy.
- Twenty-six countries reported a national infection-prevention-and-control program, yet only 16 said that more than 75% of health facilities had basic WASH and waste-management services.
- Only nine countries estimated that more than 70% of national antibiotic consumption came from the WHO Access group. Reference laboratories in 27 countries could test susceptibility for all GLASS bacterial pathogens, compared with 16 for all fungal pathogens.
Why this matters globally
The study supplies a shared baseline across a region with highly diverse health systems and income levels, turning 2030 ambitions into monitorable issues such as domestic financing, numerical targets, WASH, antibiotic mix, and fungal diagnostics. Policymakers can use the results to prioritize gaps and standardize repeat reporting. Counts of policies or capabilities, however, should not be presented as demonstrated reductions in infections, deaths, or inappropriate antibiotic use.
Thai researcher contribution
Nuntiya Somjetanakul of the Medicines Regulation Division, Thai Food and Drug Administration, Ministry of Public Health, is the Thai-affiliated author in a 33-author, 28-country network. Participation by Thailand's medicines regulator connects national policy and antibiotic-use perspectives to the regional baseline. Public records do not allocate specific data or analytical tasks to each author, so individual contributions should not be inferred beyond the documented affiliation.
Limitations to consider
These are cross-sectional national data assembled for a conference, and some indicators use 27 rather than 28 countries, indicating variable completeness. The abstract does not describe cross-source verification or harmonization of national definitions. Country aggregates may hide subnational and facility inequalities, while the existence of a plan, program, or laboratory capability does not establish quality, coverage, routine use, or patient outcomes. Selected declaration targets were assessed without a time series, so neither trend nor causality can be inferred.